Search

Displaying results 1411 - 1420 of 10000 in total
  1. Target

    Zinc finger and BTB domain-containing protein 7A

    go.drugbank.com/bio_entities/BE0012406
    TargetHumans

    Specifically represses the transcription of the tumor suppressor ARF isoform from the CDKN2A gene (By similarity). Efficiently abrogates E2F1-dependent CDKN2A transactivation (By similarity). … Directly and specifically binds to the consensus sequence 5'-[GA][CA]GACCCCCCCCC-3' and represses transcription both by regulating the organization of chromatin and through the direct recruitment of transcription

    Polypeptides: Zinc finger and BTB domain-containing protein 7ASynonyms: POZ and Krueppel erythroid myeloid ontogenic factor
  2. Drug

    Glycine

    go.drugbank.com/drugs/DB00145
    ApprovedInvestigationalNutraceuticalVet approved

    It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.

    Mixtures: Aminosyn II and Dextrose, Aminosyn II and DextroseCategories: Blood and Blood Forming Organs, Amino Acids, Peptides, and Proteins
  3. Drug

    Belimumab

    go.drugbank.com/drugs/DB08879
    ApprovedInvestigational

    [A251495, L42705] By binding to BLyS and blocking its interaction with B cell receptors, belimumab inhibits the survival of B cells. … [A251520] It is currently used to treat SLE and lupus nephritis.[L42630]

    Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating AgentsProducts: Benlysta Powder for Solution for Infusion 120mg
  4. Target

    A disintegrin and metalloproteinase with thrombospondin motifs 4

    go.drugbank.com/bio_entities/BE0004687
    EnzymeTargetHumans

    Cleaves aggrecan, a cartilage proteoglycan, at the '392-Glu-|-Ala-393' site and may be involved in its turnover (PubMed:10356395, PubMed:10827174). Also cleaves COMP (PubMed:39672391). … May play an important role in the destruction of aggrecan in arthritic diseases. Could be a critical factor in the exacerbation of neurodegeneration in Alzheimer disease

    Polypeptides: A disintegrin and metalloproteinase with thrombospondin motifs 4
  5. Target

    A disintegrin and metalloproteinase with thrombospondin motifs 13

    go.drugbank.com/bio_entities/BE0009336
    EnzymeTargetHumans

    Cleaves the vWF multimers in plasma into smaller forms thereby controlling vWF-mediated platelet thrombus formation

    Polypeptides: A disintegrin and metalloproteinase with thrombospondin motifs 13
  6. Target

    T-cell immunoreceptor with Ig and ITIM domains

    go.drugbank.com/bio_entities/BE0010742
    TargetHumans

    In turn, inhibits PI3K and MAPK signaling cascades (PubMed:23154388). … In addition, associates with beta-arrestin-2/ARRB2 to recruit SHIP1/INPP5D that suppresses autoubiquitination of TRAF6 and subsequently inhibits NF-kappa-B signaling pathway (PubMed:24817116).

    Polypeptides: T-cell immunoreceptor with Ig and ITIM domainsSynonyms: V-set and immunoglobulin domain-containing protein 9, V-set and transmembrane domain-containing protein 3
  7. Drug

    Brigatinib

    go.drugbank.com/drugs/DB12267
    ApprovedInvestigational

    [A31313] Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.[L1026] … Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR).

    Categories: Antineoplastic and Immunomodulating AgentsProducts: ALUNBRIG FILM-COATED TABLET 180mg, Alunbrig (Brigatinib) 180mg Film-Coated Tablet
  8. Drug

    Dyphylline

    go.drugbank.com/drugs/DB00651
    ApprovedWithdrawn

    Dyphylline is a theophylline derivative with broncho- and vasodilator properties. It is typically used in the management of asthma, cardiac dyspnea, and bronchitis.

    Mixtures: Dyphylline and GuaifenesinCategories: Xanthines and Adrenergics, diprophylline and adrenergics
  9. Drug

    Chlorprothixene

    go.drugbank.com/drugs/DB01239
    ApprovedInvestigationalWithdrawn

    Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors.

    Products: CHLORPROTHIXEN-NEURAX 15MG, CHLORPROTHIXEN-NEURAX 50MG
  10. Drug

    Darunavir

    go.drugbank.com/drugs/DB01264
    ApprovedInvestigational

    [A191682] Clinical trials are underway and are expected to conclude in August 2020.[L12066] … [A2278,A2281] It was initially approved by the FDA in 2006.

    Categories: darunavir and ritonavir, darunavir and cobicistatProducts: Darunavir 600 and 800 mg, TABLET 150MG